Ondansetron Attenuates Bone Cancer Pain Through The Inhibition Of Fos In The Descending Facilitation Related Nuclei

Zhang-Xiang Huang,Cai-Yang Chen,Yan He,Wei-Qing Ma,Fei-Xiang Wu,Zhi-Jie Lu,Wei-Feng Yu
2018-01-01
Abstract:Most cancer patients with bone metastasis experience severe pain. However, the treatment for this type of pain is limited by our understanding of its underlying mechanism. A large number of studies have shown that the activation of descending facilitatory system is critical in the maintenance of many chronic pain states. We used Walker 256 cell to establish a rat bone cancer model. Immunohistochemistry was employed to investigate the expression of Fos in the spinal cord and descending facilitation related nuclei (ACC, PAG, RVM) of rats at different stages of cancer development. Our results indicated that Fos expressions in these sites were all significantly upregulated in bone cancer rats. Furthermore, intrathecal injection of ondansetron attenuated bone cancer induced pain behavior as well as the expression of Fos in ACC, PAG and RVM. These data suggest that the descending facilitatory system plays an important part in the maintenance of bone cancer pain, and 5-HT3 receptor antagonist might be a possible non-opioid pain reliever in the management of bone cancer pain.
What problem does this paper attempt to address?